ENVERIC BIOSCIENCES INC (ENVB) Stock Price, Quote, News and Overview
NASDAQ:ENVB - Nasdaq - US29405E4061 - Common Stock - Currency: USD
ENVB Quote, Performance and Key Statistics
NASDAQ:ENVB (4/17/2025, 8:15:28 PM)
1.17
-0.06 (-4.88%)
The current stock price of ENVB is 1.17 USD. In the past month the price decreased by -32.37%. In the past year, price decreased by -91.14%.
ENVB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.83 | 257.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
| MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
| PFE | PFIZER INC | 7.12 | 125.57B | ||
| SNY | SANOFI-ADR | 11.41 | 124.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
| GSK | GSK PLC-SPON ADR | 8.32 | 72.88B | ||
| ZTS | ZOETIS INC | 25.11 | 66.32B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.47B |
Related stock screener links
About ENVB
Company Profile
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. The company is headquartered in Naples Florida, Florida and currently employs 7 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. The company is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The firm is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The company has created over 1,000 novel psychedelic molecular compounds and derivatives.
Company Info
ENVERIC BIOSCIENCES INC
4851 Tamiami Trail N, Suite 200
Naples Florida FLORIDA 34103 US
CEO: David Johnson
Employees: 7
Company Website: https://www.enveric.com/
Investor Relations: https://www.enveric.com/investors/
Phone: 12393021707
ENVERIC BIOSCIENCES INC / ENVB FAQ
What is the stock price of ENVERIC BIOSCIENCES INC today?
The current stock price of ENVB is 1.17 USD. The price decreased by -4.88% in the last trading session.
What is the ticker symbol for ENVERIC BIOSCIENCES INC stock?
The exchange symbol of ENVERIC BIOSCIENCES INC is ENVB and it is listed on the Nasdaq exchange.
On which exchange is ENVB stock listed?
ENVB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENVERIC BIOSCIENCES INC stock?
7 analysts have analysed ENVB and the average price target is 55.9 USD. This implies a price increase of 4677.44% is expected in the next year compared to the current price of 1.17. Check the ENVERIC BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENVERIC BIOSCIENCES INC worth?
ENVERIC BIOSCIENCES INC (ENVB) has a market capitalization of 2.89M USD. This makes ENVB a Nano Cap stock.
How many employees does ENVERIC BIOSCIENCES INC have?
ENVERIC BIOSCIENCES INC (ENVB) currently has 7 employees.
What are the support and resistance levels for ENVERIC BIOSCIENCES INC (ENVB) stock?
ENVERIC BIOSCIENCES INC (ENVB) has a resistance level at 1.2. Check the full technical report for a detailed analysis of ENVB support and resistance levels.
Should I buy ENVERIC BIOSCIENCES INC (ENVB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENVB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENVB, evaluating the profitability, health, valuation and growth aspects
- ENVERIC BIOSCIENCES INC (ENVB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENVERIC BIOSCIENCES INC (ENVB) Sales and EPS estimates to see what analysts future expectations are.
- ENVERIC BIOSCIENCES INC (ENVB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENVERIC BIOSCIENCES INC (ENVB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENVERIC BIOSCIENCES INC (ENVB) Stock Chart to make your own analysis
- ENVERIC BIOSCIENCES INC (ENVB) Latest news and press-releases to stay up to date.
Does ENVERIC BIOSCIENCES INC (ENVB) stock pay dividends?
ENVB does not pay a dividend.
When does ENVERIC BIOSCIENCES INC (ENVB) report earnings?
ENVERIC BIOSCIENCES INC (ENVB) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of ENVERIC BIOSCIENCES INC (ENVB)?
ENVERIC BIOSCIENCES INC (ENVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.76).
ENVB Technical Analysis
ENVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENVB. The financial health of ENVB is average, but there are quite some concerns on its profitability.
ENVB Financial Highlights
Over the last trailing twelve months ENVB reported a non-GAAP Earnings per Share(EPS) of -12.76. The EPS decreased by -161.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -310.62% | ||
| ROE | -601.14% | ||
| Debt/Equity | 0 |
ENVB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ENVB. The Buy consensus is the average rating of analysts ratings from 7 analysts.